2024 年业绩符合我们预期公司公布2024 年业绩:收入5.94 亿美元,同比+6.1%,持续经营业务毛利润2.72 亿美元,对应毛利率45.8%,归母净利润29.6 亿美元,净利润28.6 亿美元,盈利能力同比大幅提升,主要因传奇生物解除并表后确认投资收益32.3 亿美元,符合我们预期。发展趋势生命科学:蛋白强劲增长,不断推出高效领先的技术平台。2024 年,蛋白业务占生命科学收入比例为25%...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.